Publication:
One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study

Simple item page
dc.contributor.authorPaitazoglou, Christina
dc.contributor.authorBergmann, Martin W.
dc.contributor.authorÖZDEMİR, Ramazan
dc.contributor.authorPfister, Roman
dc.contributor.authorBartunek, Jozef
dc.contributor.authorKILIÇ, TEOMAN
dc.contributor.authorLauten, Alexander
dc.contributor.authorSchmeisser, Alexander
dc.contributor.authorZOGHİ, MEHDİ
dc.contributor.authorAnker, Stefan D.
dc.contributor.authorSievert, Horst
dc.contributor.authorMahfoud, Felix
dc.contributor.institutionauthorÖZDEMİR, RAMAZAN
dc.date.accessioned2021-03-16T20:59:10Z
dc.date.available2021-03-16T20:59:10Z
dc.date.issued2021-03-01T00:00:00Z
dc.description.abstractAims Attenuating exercise-induced elevated left atrial pressure with an atrial shunt device is under clinical investigation for treatment of symptomatic heart failure (HF). Methods and results PRELIEVE was a prospective, non-randomised, multicentre, first-in-man study in symptomatic HF patients with reduced (HFrEF) or preserved (HFpEF) ejection fraction and pulmonary capillary wedge pressure (PCWP) >= 15 mmHg at rest or >= 25 mmHg during exercise. Here, we provide follow-up data up to 1 year after implantation of the Atrial Flow Regulator (AFR) device. The AFR was successfully implanted in 53 patients (HFrEF n = 24 and HFpEF n = 29). Two patients were not enrolled due to an unsuccessful transseptal puncture. There was one device embolisation into the left atrium, which required surgical removal. One patient experienced a serious procedure-related adverse event (post-procedural bleeding and syncope). All patients with sufficient echocardiography readout confirmed device patency with left-right shunt both at 3 (n = 47/51, 92%) and 12 (n = 45/49, 92%) months. At 3 months, rest PCWP decreased by 5 (-12, 0) mmHg (P = 0.0003, median Q1, Q3). No patient developed a stroke, worsening of right heart function or significant increase of pulmonary artery pressure. Six (6/53, 11%) patients were hospitalised for worsening of HF and three (3/53, 6%) patients died. We observed improvements in New York Heart Association functional class, 6-min walking distance and quality of life (Kansas City Cardiomyopathy Questionnaire) in certain patients. Conclusions Implantation of the AFR device in HF patients was feasible. No shunt occlusion, stroke or new right HF was observed during the 1-year follow-up, with clinical improvements in certain patients.
dc.identifier.citationPaitazoglou C., Bergmann M. W. , ÖZDEMİR R., Pfister R., Bartunek J., KILIÇ T., Lauten A., Schmeisser A., ZOGHİ M., Anker S. D. , et al., -One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study-, EUROPEAN JOURNAL OF HEART FAILURE, 2021
dc.identifier.doi10.1002/ejhf.2119
dc.identifier.pubmed33555114
dc.identifier.scopus85102196307
dc.identifier.urihttp://hdl.handle.net/20.500.12645/28577
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/ejhf.2119
dc.identifier.wosWOS:000625565600001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectheart failure
dc.titleOne-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study
dc.typeArticle
dspace.entity.typePublication
local.avesis.id2fbe7f33-f716-4e13-b3df-19303880b646
local.publication.isinternational1
relation.isAuthorOfPublication6384fc88-e60f-4402-bacf-1f1b2120fb58
relation.isAuthorOfPublication.latestForDiscovery6384fc88-e60f-4402-bacf-1f1b2120fb58
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients the PRELIEVE study.pdf
Size:
7.67 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler